49 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
of age-related cognitive decline. When evaluated in the Morris-Water-Maze test, rats show cognitive deficits starting at 20 to 22 months of age … , which is equivalent to approximately 60 years of age in humans. Of note, because the deficits in Morris-Water-Maze performance can be fully reversed
8-K
EX-99.1
CRVO
CervoMed Inc
6 Sep 23
Other Events
4:05pm
.”
A water-marked version of the manuscript, entitled “Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients
425
EX-2.1
CRVO
CervoMed Inc
30 Mar 23
Business combination disclosure
8:51am
, surface water, groundwater, drinking water supply, surface and subsurface soils and strata, wetlands, plant and animal life or any other natural resource
8-K
EX-2.1
rddi1yjw88ovc1
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
424B5
pbkaveq 59o
22 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-1.1
q6xylz3u50
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
424B5
fosa6mnqy3
17 Feb 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
oeestnf4x5o he4y2
16 Feb 21
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
8:10am
8-K
EX-99.1
ffh56mjxvesqiw0i0mm
12 Feb 21
Note Regarding Forward-looking Statements
8:19am
424B5
hd2gi55q 733an7
11 Feb 21
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
pnfn vf1q
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
424B2
taeuk8
2 Oct 20
Prospectus for primary offering
4:16pm
8-K
EX-10.1
9ce yqkk1ap
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm